Intratumoral Fibrosis and Tumor Growth Pattern as Prognostic Factors in Optimally Resected Pancreatic Neuroendocrine Neoplasms An Analysis of 168 Cases

被引:12
作者
Chatterjee, Deyali [1 ]
Trikalinos, Nikolaos A. [2 ]
Williams, Greg A. [3 ]
Liu, Jingxia [3 ]
Hawkins, William G. [3 ]
Hammill, Chet [3 ]
机构
[1] Washington Univ, Dept Pathol & Immunol, St Louis, MO 63110 USA
[2] Washington Univ, Dept Med, St Louis, MO USA
[3] Washington Univ, Dept Surg, St Louis, MO 63110 USA
关键词
fibrosis; neuroendocrine tumors; recurrence; tumor growth pattern; SURVIVAL; CANCER; GEMCITABINE; STROMA; TRIAL;
D O I
10.1097/MPA.0000000000001478
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objectives Pancreatic neuroendocrine neoplasms (PanNENs) can recur after curative resection. We sought to establish the significance of tumor fibrosis and tumor growth pattern as predictors of recurrence-free survival and overall survival. Methods A retrospective query of an institutional surgical database was performed from 2000 to 2018 to identify optimally resected PanNENs. All eligible slides were reviewed by an experienced gastrointestinal pathologist for established histopathologic prognostic factors, as well as fibrosis and tumor growth pattern. We evaluated the effect of the interested variables through Cox proportional hazards models. Results One hundred sixty-eight cases were considered. The majority of patients (90%) had grade 1 or 2 tumors, 46% showed significant fibrosis, and 22% demonstrated an infiltrative growth pattern. Twenty-one percent of patients had a recurrence. In multivariable analysis, lymphovascular invasion with a hazard ratio (HR) of 5.1 and infiltrative growth pattern (HR, 2.8) were significantly associated with increased risk of recurrence and increased risk of death (HR, 3.6 and 2.7, respectively). There was a significant decrease in recurrence-free survival and overall survival for fibrosis and infiltrative growth pattern. Conclusions In optimally resected PanNENs, the presence of fibrosis and infiltrative growth pattern are significant risk factors for recurrence and/or decreased survival.
引用
收藏
页码:255 / 260
页数:6
相关论文
共 38 条
[1]  
[Anonymous], CRYSTENGCOMM
[2]   Targeting stroma in pancreatic cancer: Promises and failures of targeted therapies [J].
Bahrami, Afsane ;
Khazaei, Majid ;
Bagherieh, Fariba ;
Ghayour-Mobarhan, Majid ;
Maftouh, Mina ;
Hassanian, Seyed Mahdi ;
Avan, Amir .
JOURNAL OF CELLULAR PHYSIOLOGY, 2017, 232 (11) :2931-2937
[3]   FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer [J].
Conroy, T. ;
Hammel, P. ;
Hebbar, M. ;
Ben Abdelghani, M. ;
Wei, A. C. ;
Raoul, J. -L. ;
Chone, L. ;
Francois, E. ;
Artru, P. ;
Biagi, J. J. ;
Lecomte, T. ;
Assenat, E. ;
Faroux, R. ;
Ychou, M. ;
Volet, J. ;
Sauvanet, A. ;
Breysacher, G. ;
Di Fiore, F. ;
Cripps, C. ;
Kavan, P. ;
Texereau, P. ;
Bouhier-Leporrier, K. ;
Khemissa-Akouz, F. ;
Legoux, J. -L. ;
Juzyna, B. ;
Gourgou, S. ;
O'Callaghan, C. J. ;
Jouffroy-Zeller, C. ;
Rat, P. ;
Malka, D. ;
Castan, F. ;
Bachet, J. -B. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (25) :2395-2406
[4]   Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States [J].
Dasari, Arvind ;
Shen, Chan ;
Halperin, Daniel ;
Zhao, Bo ;
Zhou, Shouhao ;
Xu, Ying ;
Shih, Tina ;
Yao, James C. .
JAMA ONCOLOGY, 2017, 3 (10) :1335-1342
[5]   HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer [J].
Doherty, Gary J. ;
Tempero, Margaret ;
Corrie, Pippa G. .
FUTURE ONCOLOGY, 2018, 14 (01) :13-22
[6]   Intra-abdominal fibrosis in a recent cohort of patients with neuroendocrine ('carcinoid') tumours of the small bowel [J].
Druce, M. R. ;
Bharwani, N. ;
Akker, S. A. ;
Drake, W. M. ;
Rockall, A. ;
Grossman, A. B. .
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2010, 103 (03) :177-185
[7]   Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression [J].
Duan, Wanxing ;
Chen, Ke ;
Jiang, Zhengdong ;
Chen, Xin ;
Sun, Liankang ;
Li, Jiahui ;
Lei, Jianjun ;
Xu, Qinhong ;
Ma, Jiguang ;
Li, Xuqi ;
Han, Liang ;
Wang, Zheng ;
Wu, Zheng ;
Wang, Fengfei ;
Wu, Erxi ;
Ma, Qingyong ;
Ma, Zhenhua .
CANCER LETTERS, 2017, 385 :225-233
[8]   Progesterone Receptor and PTEN Expression Predict Survival in Patients With Low- and Intermediate-Grade Pancreatic Neuroendocrine Tumors [J].
Estrella, Jeannelyn S. ;
Broaddus, Russell R. ;
Mathews, Amber ;
Milton, Denai R. ;
Yao, James C. ;
Wang, Huamin ;
Rashid, Asif .
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2014, 138 (08) :1027-1036
[9]   Growth Pattern, an Important Pathologic Prognostic Parameter for Clear Cell Renal Cell Carcinoma [J].
Fukatsu, Akitoshi ;
Tsuzuki, Toyomori ;
Sassa, Naoto ;
Nishikimi, Toshinori ;
Kimura, Tohoru ;
Majima, Tsuyoshi ;
Yoshino, Yasushi ;
Hattori, Ryohei ;
Gotoh, Momokazu .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2013, 140 (04) :500-505
[10]   Novel recurrence risk stratification of resected pancreatic neuroendocrine tumor [J].
Gao, Heli ;
Liu, Liang ;
Wang, Wenquan ;
Xu, Huaxiang ;
Jin, Kaizhou ;
Wu, Chuntao ;
Qi, Zihao ;
Zhang, Shirong ;
Liu, Chen ;
Xu, Jinzhi ;
Ni, Quanxing ;
Yu, Xianjun .
CANCER LETTERS, 2018, 412 :188-193